Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
81,149,970
-
Total 13F shares
-
31,640,426
-
Share change
-
+3,578,351
-
Total reported value
-
$1,196,963,610
-
Price per share
-
$37.93
-
Number of holders
-
101
-
Value change
-
+$170,619,687
-
Number of buys
-
71
-
Number of sells
-
21
Institutional Holders of Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) as of Q1 2024
As of 31 Mar 2024,
Spyre Therapeutics, Inc. - Common Stock, $0.0001 par value (SYRE) was held by
101 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,640,426 shares.
The largest 10 holders included
FMR LLC, PERCEPTIVE ADVISORS LLC, RTW INVESTMENTS, LP, VR Adviser, LLC, COMMODORE CAPITAL LP, Avoro Capital Advisors LLC, Deep Track Capital, LP, ADAGE CAPITAL PARTNERS GP, L.L.C., WELLINGTON MANAGEMENT GROUP LLP, and FRANKLIN RESOURCES INC.
This page lists
101
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.